Jaypirca
Jaypirca ingredients
| Active ingredient | Strength |
|---|---|
| Pirtobrutinib | 100 mg/1, 50 mg/1 |
What Jaypirca is used for
The FDA lists the approved uses on the official label (below). In the EU, pirtobrutinib is approved as Jaypirca for:
Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor. Jaypirca as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL).
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Jaypirca
- Generic name
- Pirtobrutinib
- Made by
- Eli Lilly and Company
- Forms
- Tablet, Coated
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA216059
- On the US market since
- 2023
Official information
- MedlinePlus drug information (search for Pirtobrutinib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Jaypirca?
Jaypirca (Pirtobrutinib) is a cancer medicine made by Eli Lilly and Company, approved by the US FDA.
What are the ingredients of Jaypirca?
Jaypirca contains Pirtobrutinib (100 mg/1, 50 mg/1).
Is Jaypirca approved in Europe?
The same active substance is approved in the EU as Jaypirca.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA